{"id":16781,"date":"2024-12-04T22:46:16","date_gmt":"2024-12-04T14:46:16","guid":{"rendered":"https:\/\/flcube.com\/?p=16781"},"modified":"2024-12-04T22:46:18","modified_gmt":"2024-12-04T14:46:18","slug":"coherus-biosciences-sells-udenyca-franchise-to-intas-pharmaceuticals-in-asset-purchase-deal","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=16781","title":{"rendered":"Coherus BioSciences Sells Udenyca Franchise to Intas Pharmaceuticals in Asset Purchase Deal"},"content":{"rendered":"\n

US-based Coherus BioSciences, Inc. (Coherus, NASDAQ: CHRS<\/a>) has announced an asset purchase agreement with Indian-headquartered Intas Pharmaceuticals Ltd. (Intas) regarding the divestment of Udenyca (pegfilgrastim-cbqv), a filgrastim biosimilar used to reduce the risk of febrile neutropenia in cancer patients post-chemotherapy.<\/p>\n\n\n\n

Terms of the Agreement and Product Transfer<\/strong>
Under the agreement, Coherus will transfer its Udenyca franchise to Intas, which includes the Udenyca pre-filled syringe, the Udenyca autoinjector, and Udenyca Onbody, a wearable injector. Intas\u2019 US unit, Accord BioPharma, Inc., will assume full responsibility for the Udenyca franchise in the US once the deal is closed.<\/p>\n\n\n\n

Financial Details and Coherus’ Plans<\/strong>
Coherus will receive an upfront cash payment of USD 483.4 million and two net sales milestone payments totaling USD 75.0 million. The company intends to use a portion of the transaction proceeds to fully repay its existing convertible notes of USD 230.0 million due in April 2026 and to buy out certain royalty obligations related to Udenyca, amounting to USD 49.1 million.<\/p>\n\n\n\n

Coherus’ Future Focus on Tumor Immunology<\/strong>
Following the divestiture of the Udenyca franchise, Coherus plans to shift its focus to its tumor immunology programs. This includes Loqtorzi (toripalimab-tpzi), a PD-1 inhibitor partnered with Junshi Biosciences that has received FDA approval for nasopharyngeal carcinoma (NPC), as well as other key programs such as the IL-27 antagonist casdozokitug and CCR8 antibody CHS-114.-Fineline Info & Tech<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

US-based Coherus BioSciences, Inc. (Coherus, NASDAQ: CHRS) has announced an asset purchase agreement with Indian-headquartered…<\/p>\n","protected":false},"author":1,"featured_media":16783,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[613,1259,1307],"class_list":["post-16781","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-coherus-biosciences","tag-intas-pharmaceuticals","tag-nasdaq-chrs"],"yoast_head":"\nCoherus BioSciences Sells Udenyca Franchise to Intas Pharmaceuticals in Asset Purchase Deal - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"US-based Coherus BioSciences, Inc. (Coherus, NASDAQ: CHRS) has announced an asset purchase agreement with Indian-headquartered Intas Pharmaceuticals Ltd. (Intas) regarding the divestment of Udenyca (pegfilgrastim-cbqv), a filgrastim biosimilar used to reduce the risk of febrile neutropenia in cancer patients post-chemotherapy.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=16781\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Coherus BioSciences Sells Udenyca Franchise to Intas Pharmaceuticals in Asset Purchase Deal\" \/>\n<meta property=\"og:description\" content=\"US-based Coherus BioSciences, Inc. (Coherus, NASDAQ: CHRS) has announced an asset purchase agreement with Indian-headquartered Intas Pharmaceuticals Ltd. (Intas) regarding the divestment of Udenyca (pegfilgrastim-cbqv), a filgrastim biosimilar used to reduce the risk of febrile neutropenia in cancer patients post-chemotherapy.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=16781\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-04T14:46:16+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-04T14:46:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/0498.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"425\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=16781#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=16781\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Coherus BioSciences Sells Udenyca Franchise to Intas Pharmaceuticals in Asset Purchase Deal\",\"datePublished\":\"2024-12-04T14:46:16+00:00\",\"dateModified\":\"2024-12-04T14:46:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=16781\"},\"wordCount\":233,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=16781#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/0498.png\",\"keywords\":[\"Coherus Biosciences\",\"Intas Pharmaceuticals\",\"NASDAQ: CHRS\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=16781#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=16781\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=16781\",\"name\":\"Coherus BioSciences Sells Udenyca Franchise to Intas Pharmaceuticals in Asset Purchase Deal - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=16781#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=16781#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/0498.png\",\"datePublished\":\"2024-12-04T14:46:16+00:00\",\"dateModified\":\"2024-12-04T14:46:18+00:00\",\"description\":\"US-based Coherus BioSciences, Inc. (Coherus, NASDAQ: CHRS) has announced an asset purchase agreement with Indian-headquartered Intas Pharmaceuticals Ltd. (Intas) regarding the divestment of Udenyca (pegfilgrastim-cbqv), a filgrastim biosimilar used to reduce the risk of febrile neutropenia in cancer patients post-chemotherapy.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=16781#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=16781\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=16781#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/0498.png\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/0498.png\",\"width\":1080,\"height\":425,\"caption\":\"Coherus BioSciences Sells Udenyca Franchise to Intas Pharmaceuticals in Asset Purchase Deal\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=16781#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Coherus BioSciences Sells Udenyca Franchise to Intas Pharmaceuticals in Asset Purchase Deal\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Coherus BioSciences Sells Udenyca Franchise to Intas Pharmaceuticals in Asset Purchase Deal - Insight, China's Pharmaceutical Industry","description":"US-based Coherus BioSciences, Inc. (Coherus, NASDAQ: CHRS) has announced an asset purchase agreement with Indian-headquartered Intas Pharmaceuticals Ltd. (Intas) regarding the divestment of Udenyca (pegfilgrastim-cbqv), a filgrastim biosimilar used to reduce the risk of febrile neutropenia in cancer patients post-chemotherapy.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=16781","og_locale":"en_US","og_type":"article","og_title":"Coherus BioSciences Sells Udenyca Franchise to Intas Pharmaceuticals in Asset Purchase Deal","og_description":"US-based Coherus BioSciences, Inc. (Coherus, NASDAQ: CHRS) has announced an asset purchase agreement with Indian-headquartered Intas Pharmaceuticals Ltd. (Intas) regarding the divestment of Udenyca (pegfilgrastim-cbqv), a filgrastim biosimilar used to reduce the risk of febrile neutropenia in cancer patients post-chemotherapy.","og_url":"https:\/\/flcube.com\/?p=16781","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-12-04T14:46:16+00:00","article_modified_time":"2024-12-04T14:46:18+00:00","og_image":[{"width":1080,"height":425,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/0498.png","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=16781#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=16781"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Coherus BioSciences Sells Udenyca Franchise to Intas Pharmaceuticals in Asset Purchase Deal","datePublished":"2024-12-04T14:46:16+00:00","dateModified":"2024-12-04T14:46:18+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=16781"},"wordCount":233,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=16781#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/0498.png","keywords":["Coherus Biosciences","Intas Pharmaceuticals","NASDAQ: CHRS"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=16781#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=16781","url":"https:\/\/flcube.com\/?p=16781","name":"Coherus BioSciences Sells Udenyca Franchise to Intas Pharmaceuticals in Asset Purchase Deal - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=16781#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=16781#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/0498.png","datePublished":"2024-12-04T14:46:16+00:00","dateModified":"2024-12-04T14:46:18+00:00","description":"US-based Coherus BioSciences, Inc. (Coherus, NASDAQ: CHRS) has announced an asset purchase agreement with Indian-headquartered Intas Pharmaceuticals Ltd. (Intas) regarding the divestment of Udenyca (pegfilgrastim-cbqv), a filgrastim biosimilar used to reduce the risk of febrile neutropenia in cancer patients post-chemotherapy.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=16781#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=16781"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=16781#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/0498.png","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/0498.png","width":1080,"height":425,"caption":"Coherus BioSciences Sells Udenyca Franchise to Intas Pharmaceuticals in Asset Purchase Deal"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=16781#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Coherus BioSciences Sells Udenyca Franchise to Intas Pharmaceuticals in Asset Purchase Deal"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/0498.png","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/16781","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=16781"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/16781\/revisions"}],"predecessor-version":[{"id":16784,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/16781\/revisions\/16784"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/16783"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=16781"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=16781"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=16781"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}